Tempest Therapeutics, Inc.

BiotechnologyBiotechnologyClinical-stageOncology

📍 Brisbane, CA, United States• Founded 2011

StreetZero Signal 77

Be the first to signal interest

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways with a diverse portfolio of tumor-targeted and immune-mediated product candidates. The company is developing first-in-class and potential best-in-class small molecules and is headquartered in Brisbane, California. It has a pipeline ranging from early research to later-stage investigation in randomized global studies for first-line cancer patients.

LATEST FUNDINGPrivate Placement

$7.5M

Announced 2026-10-14

TOTAL RAISED$88.2M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Tempest Therapeutics, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2011

HQBrisbane, CA, United States

Industry

Biotechnology

Investors

Versant Ventures F-Prime Capital Quan Capital Lilly Asia Ventures Foresite Capital Eight Roads Ventures

Key highlights

Completed $70 million Series B led by Versant Ventures with participation from F-Prime, Quan Capital and others.
Raised total of $88.2 million across five rounds since incorporation in 2011.
Announced up to $7.5 million private placement in 2026 to support operations.
Acquired dual-CAR T programs and extended runway to mid-2027.
Maintains pipeline in tumor-targeted and immune-mediated mechanisms for cancer treatment.